Related Experiment Video
Updated: Jun 4, 2026
Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
Pirfenidone treatment of idiopathic pulmonary fibrosis
Ye Gan1, Erica L Herzog, Richard H Gomer
1Department of Medicine, Central South University, Changsha, Hunan, China;
Abstract:
Idiopathic pulmonary fibrosis (IPF) is a discrete clinicopathologic entity defined by the presence of usual interstitial pneumonia on high-resolution CT scan and/or open lung biopsy and the absence of an alternate diagnosis or exposure explaining these findings. There are currently no FDA-approved therapies available to treat this disease, and the 5-year mortality is ∼80%. The pyridone derivative pirfenidone has been studied extensively as a possible therapeutic agent for use in this deadly disease. This review will present the unique clinical features and management issues encountered by physicians caring for IPF patients, including the poor response to conventional therapy. The biochemistry and preclinical efficacy of pirfenidone will be discussed along with a comprehensive review of the clinical efficacy, safety, and side effects and patient-centered foci such as quality of life and tolerability. It is hoped that this information will lend insight into the complex issues surrounding the use of pirfenidone in IPF and lead to further investigation of this agent as a possible therapy in this devastating disease.
Insights
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with no approved treatments. Pirfenidone shows promise as a potential therapy, with ongoing research into its efficacy, safety, and impact on patient quality of life.
Area of Science:
- Pulmonology
- Pharmacology
Background:
- Idiopathic pulmonary fibrosis (IPF) is a severe lung disease with a high mortality rate.
- Current treatments for IPF are limited, with no FDA-approved therapies available.
- Pirfenidone is a pyridone derivative investigated for its therapeutic potential in IPF.
Purpose of the Study:
- To review the clinical features and management challenges of IPF.
- To discuss the preclinical and clinical efficacy of pirfenidone in IPF.
- To evaluate the safety, side effects, tolerability, and quality of life aspects of pirfenidone treatment in IPF patients.
Main Methods:
- Literature review of pirfenidone's biochemistry and preclinical studies.
- Comprehensive analysis of clinical trial data on pirfenidone's efficacy and safety.
- Examination of patient-centered outcomes, including quality of life and tolerability.
Main Results:
- IPF is characterized by usual interstitial pneumonia and has a poor prognosis.
- Pirfenidone has demonstrated preclinical efficacy and is being studied for clinical use.
- The review covers pirfenidone's efficacy, safety, side effects, and impact on quality of life.
Conclusions:
- Pirfenidone is a potential therapeutic agent for IPF, a disease with significant unmet medical needs.
- Further investigation into pirfenidone is warranted to understand its role in managing IPF.
- Addressing patient-centered outcomes like quality of life is crucial for IPF management.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
01:25Pulmonary Function Tests
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...